Badge: Health
—
**NHS to Roll Out Rapid Cancer Jab, Drastically Cutting Hospital Time for Thousands**
**LONDON, UK** – The National Health Service (NHS) is set to revolutionize cancer treatment for thousands of patients across England by introducing a new, rapid injectable form of an immunotherapy drug. This innovative approach is expected to significantly cut hospital visit times from hours to just minutes, marking a major step forward in patient care and operational efficiency.
The drug, atezolizumab (marketed as Tecentriq), traditionally administered intravenously, will now be offered as a subcutaneous (under-the-skin) injection. This streamlined method reduces administration time to approximately seven minutes, a stark contrast to the 30 to 60 minutes required for an intravenous drip, plus the additional time for preparation and post-infusion monitoring.
This shift represents a significant logistical improvement, promising substantial benefits for both patients and the healthcare system. Patients will experience greater convenience, reduced stress, and more time away from hospital environments, allowing them to better manage their lives around treatment schedules. For the NHS, this innovation will free up valuable time for healthcare professionals, alleviate pressure on infusion units, and improve overall hospital efficiency.
It is estimated that over 3,600 cancer patients in England annually, who are currently receiving atezolizumab, stand to benefit from this accelerated treatment. Atezolizumab is used to treat various cancers, including specific types of lung, breast, liver, and bladder cancers.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, commented on the rollout: “This rapid jab is a game-changer for both patients and our healthcare system. It not only enhances the patient experience by reducing time spent in hospital but also optimizes our resources, allowing us to treat more people efficiently and effectively. It underscores our commitment to adopting cutting-edge treatments that prioritize patient well-being and convenience.”
The introduction of this subcutaneous atezolizumab marks a significant step forward in cancer care delivery within the NHS. It exemplifies how innovation can streamline complex medical procedures, making treatment more accessible and less burdensome for those battling cancer. This move is expected to pave the way for similar advancements in drug administration, further enhancing the quality and efficiency of patient care across the country.
